Cambridge, United Kingdom

Harry Finch

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Harry Finch

Introduction

Harry Finch is a notable inventor based in Cambridge, GB. He has made significant strides in the field of cancer treatment through his innovative research and development of heterocyclic compounds. His work is particularly focused on the creation of compounds that can be utilized in the treatment and prophylaxis of cancer.

Latest Patents

Harry Finch holds a patent for "Heterocyclic compounds for use in the treatment of cancer." This patent relates to heterocyclic amide derivatives and their application in combating cancer. The patent also covers compositions that contain these derivatives and the processes involved in their preparation. He has 1 patent to his name, showcasing his contribution to medical science.

Career Highlights

Finch is currently employed at Artios Pharma Limited, a company dedicated to advancing cancer therapies. His role at Artios Pharma allows him to collaborate with other experts in the field and contribute to groundbreaking research. His work is instrumental in the ongoing fight against cancer, and he is recognized for his innovative approach to drug development.

Collaborations

Harry Finch has worked alongside talented colleagues such as Peter Blencowe and Mark Charles. These collaborations have fostered an environment of innovation and creativity, leading to advancements in cancer treatment methodologies.

Conclusion

In summary, Harry Finch is a dedicated inventor whose work in developing heterocyclic compounds has the potential to significantly impact cancer treatment. His contributions through patents and collaborations highlight the importance of innovation in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…